Medtronic (MDT) Stock Price, News & Analysis

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MDT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDT, but not buy additional shares or sell existing shares.
View MDT analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued twelve-month price objectives for Medtronic's shares. Their MDT share price targets range from $82.00 to $106.00. On average, they predict the company's stock price to reach $94.91 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts price targets for MDT or view top-rated stocks among Wall Street analysts.

Medtronic's stock was trading at $82.38 at the beginning of 2024. Since then, MDT shares have decreased by 3.8% and is now trading at $79.25.
View the best growth stocks for 2024 here.

Medtronic saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 11,530,000 shares, an increase of 36.4% from the February 29th total of 8,450,000 shares. Based on an average trading volume of 6,070,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.9% of the shares of the company are short sold.
View Medtronic's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our MDT earnings forecast.

Medtronic plc (NYSE:MDT) posted its quarterly earnings results on Tuesday, February, 20th. The medical technology company reported $1.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.26 by $0.04. The medical technology company earned $8.09 billion during the quarter, compared to the consensus estimate of $7.95 billion. Medtronic had a trailing twelve-month return on equity of 13.71% and a net margin of 13.00%. The business's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.30 EPS.
Read the conference call transcript.

Medtronic declared a quarterly dividend on Thursday, March 7th. Investors of record on Friday, March 22nd will be paid a dividend of $0.69 per share on Friday, April 12th. This represents a $2.76 annualized dividend and a dividend yield of 3.48%. The ex-dividend date of this dividend is Thursday, March 21st.
Read our dividend analysis for MDT.

Medtronic (NYSE:MDT) pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.44%. The company has been increasing its dividend for 47 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 87.90%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MDT will have a dividend payout ratio of 50.55% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MDT.

ETFs with the largest weight of Medtronic (NYSE:MDT) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Absolute Select Value ETF (ABEQ), American Century Focused Large Cap Value ETF (FLV), Leatherback Long/Short Alternative Yield ETF (LBAY), Cambiar Aggressive Value ETF (CAMX), USCF Dividend Income Fund (UDI), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and Emerge EMPWR Sustainable Dividend Equity ETF (EMCA).

Medtronic updated its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of 5.190-5.210 for the period, compared to the consensus estimate of 5.160. The company issued revenue guidance of $32.1 billion-$32.3 billion, compared to the consensus revenue estimate of $32.1 billion.

1,925 employees have rated Medtronic Chief Executive Officer Omar S. Ishrak on Glassdoor.com. Omar S. Ishrak has an approval rating of 92% among the company's employees. This puts Omar S. Ishrak in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), Home Depot (HD) and Walmart (WMT).

Medtronic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Miller Howard Investments Inc. NY (0.05%), Perpetual Ltd (0.03%), Factory Mutual Insurance Co. (0.02%), CWM LLC (0.02%), Cardinal Capital Management Inc. (0.02%) and Czech National Bank (0.02%). Insiders that own company stock include Bradley E Lerman, Brett A Wall, Brett A Wall, Carol A Surface, Geoffrey Martha, Gregory L Smith, Hoedt Rob Ten, John R Liddicoat, Karen L Parkhill, Karen L Parkhill, Michael Marinaro, Richard H Anderson, Robert John White and Sean Salmon.
View institutional ownership trends.

Shares of MDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.